Glycogenosis type II (acid maltase deficiency)
- PMID: 7603530
- DOI: 10.1002/mus.880181414
Glycogenosis type II (acid maltase deficiency)
Abstract
Glycogen storage disease type II (GSD II/glycogenosis type II/Pompe's disease/acid maltase deficiency) is caused by the deficiency of lysosomal alpha-glucosidase resulting in lysosomal accumulation of glycogen. The disease is inherited as an autosomal recessive trait and is clinically heterogeneous. Early and late onset phenotypes are distinguished. Insight in the molecular nature of the lysosomal alpha-glucosidase deficiency and the underlying genetic defect has increased significantly during the past decade. This minireview on GSD II was written at the occasion of The International Symposium on Glycolytic and Mitochondrial Defects in Muscle and Nerve, held in Osaka, Japan, July 1994. It is an update of current literature, but also includes original data from the collaborating authors on mutations occurring in the lysosomal alpha-glucosidase gene and on prenatal diagnosis by chorionic villus sampling. The genotype-phenotype correlation and the prospects for therapy are addressed.
Similar articles
-
Genetic defects in patients with glycogenosis type II (acid maltase deficiency).Muscle Nerve Suppl. 1995;3:S70-4. doi: 10.1002/mus.880181415. Muscle Nerve Suppl. 1995. PMID: 7603531 Review.
-
Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient with an unusual phenotype.Neurology. 2005 Jan 25;64(2):368-70. doi: 10.1212/01.WNL.0000149528.95362.20. Neurology. 2005. PMID: 15668445
-
Glycogen-storage disease type II (acid maltase deficiency): identification of a novel small deletion (delCC482+483) in French patients.Biochem Biophys Res Commun. 1997 Jun 9;235(1):138-41. doi: 10.1006/bbrc.1997.6749. Biochem Biophys Res Commun. 1997. PMID: 9196050
-
Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.Hum Mutat. 2004 Jan;23(1):47-56. doi: 10.1002/humu.10286. Hum Mutat. 2004. PMID: 14695532
-
Late-onset Pompe's disease.Semin Neurol. 2012 Nov;32(5):506-11. doi: 10.1055/s-0033-1334469. Epub 2013 May 15. Semin Neurol. 2012. PMID: 23677658 Review.
Cited by
-
Golgi defect as a major contributor to lysosomal dysfunction.Front Cell Dev Biol. 2024 Apr 24;12:1386149. doi: 10.3389/fcell.2024.1386149. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 38721528 Free PMC article. Review.
-
Pompe disease in China: clinical and molecular characteristics.Front Cardiovasc Med. 2023 Dec 14;10:1261172. doi: 10.3389/fcvm.2023.1261172. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 38162137 Free PMC article.
-
A Comprehensive Update on Late-Onset Pompe Disease.Biomolecules. 2023 Aug 22;13(9):1279. doi: 10.3390/biom13091279. Biomolecules. 2023. PMID: 37759679 Free PMC article. Review.
-
Neuromuscular Development and Disease: Learning From in vitro and in vivo Models.Front Cell Dev Biol. 2021 Oct 27;9:764732. doi: 10.3389/fcell.2021.764732. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34778273 Free PMC article. Review.
-
Correlation of GAA Genotype and Acid-α-Glucosidase Enzyme Activity in Hungarian Patients with Pompe Disease.Life (Basel). 2021 May 31;11(6):507. doi: 10.3390/life11060507. Life (Basel). 2021. PMID: 34072668 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous